CTNI-70. LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

PURPOSE: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Rulseh, Aaron, Derner, Adam, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Trials: Non-Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651202/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.236
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky